Merck KGaA unit acquires $14 million-a-year cell imaging instrumentation maker in deal set to close in Q4.

Signaling a desire to expand within flow cytometry, EMD Millipore announced plans to acquire cell imaging instrumentation maker Amnis for an undisclosed sum. The deal, subject to regulatory approvals, is expected to close in the fourth quarter.

In acquiring Amnis—which generated $14 million in sales last year, and employs 40 people—EMD Millipore sought a business that would complement its Guava family of products, acquired with their namesake company in 2009. EMD Millipore is the life sciences division of German-owned Merck KGaA.

Jonathan DiVincenzo, head of EMD Millipore’s bioscience business unit, said that the deal would benefit the company by allowing it to offer a solution combining flow cytometry and image analysis. Amnis is EMD Millipore’s second acquisition this year. In March, it snapped up the microbiology operations of German-owned Biotest.

“The combination of Amnis with EMD Millipore will greatly accelerate development of novel applications in imaging flow cytometry, enhance our customer support, and accelerate product development,” said David A. Basiji, co-founder and CEO of Amnis.

Previous articleAdimab Signs Separate Antibody Discovery Deals with Biogen Idec and Novo Nordisk
Next articleAeterna Zentaris Reports Positive Phase III Results for AGHD Test